EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Genetic Testing for Malignant Hyperthermia Susceptibility—Threading the Needle in the Haystack

Anjan K Saha iD, Teeda Pinyavat iD

Genes · 2025

DOI: 10.3390/genes16111281 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, 2025. Verfasst von Anjan K Saha und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Columbia University Irving Medical Center, New York, NY 10032, USA. Hauptthemen laut MEDLINE: Malignant Hyperthermia, Genetic Testing, Genetic Predisposition to Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant hyperthermia (MH) is a rare pharmacogenetic disorder triggered by volatile anesthetics and succinylcholine, most often linked to pathogenic variants in RYR1, CACNA1S, and STAC3. The advent of next-generation sequencing (NGS) has transformed MH diagnostics, offering new opportunities for perioperative risk assessment as caffeine–halothane contracture testing declines. However, challenges remain, including incomplete penetrance, variable pathogenicity of variants, limited access to functional confirmatory testing, and cost. Genetic testing also raises important questions. What is the clinical utility of finding a variant of unknown significance? What are the broader implications of MH susceptibility beyond the operating room? Emerging evidence connects MH susceptibility loci to exertional heat illness (EHI), exertional rhabdomyolysis (ERM), and heat-related mortality, highlighting the need for a broader framework for genetic risk assessment. This review synthesizes historical advances, current consensus, and future directions concerning MH to guide anesthesiologists and perioperative clinicians in leveraging molecular diagnostics for personalized care and improved patient safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Malignant HyperthermiaGenetic TestingGenetic Predisposition to DiseaseHumansRyanodine Receptor Calcium Release ChannelHigh-Throughput Nucleotide SequencingCalcium Channels, L-Type

Stichwörter der Autor:innen

genetic testingmalignant hyperthermianext-generation sequencingpatient safetyperioperative medicine

Substanzen

Ryanodine Receptor Calcium Release ChannelRYR1 protein, humanCACNA1S protein, humanCalcium Channels, L-Type

Autor:innen und Institutionen

  • Department of Anesthesiology, Columbia University Irving Medical Center, New York, NY 10032, USA.

ORCID-Profile: Anjan K Saha, Teeda Pinyavat

Förderung

  • NIGMS NIH HHS

Zitieren

APA

Saha, A. K., & Pinyavat, T. (2025). Genetic Testing for Malignant Hyperthermia Susceptibility—Threading the Needle in the Haystack. Genes. https://doi.org/10.3390/genes16111281

Vancouver

Saha AK, Pinyavat T. Genetic Testing for Malignant Hyperthermia Susceptibility—Threading the Needle in the Haystack. Genes. 2025. doi:10.3390/genes16111281

BibTeX
@article{Saha2025,
  author = {Saha, Anjan K and Pinyavat, Teeda},
  title = {Genetic Testing for Malignant Hyperthermia Susceptibility—Threading the Needle in the Haystack},
  journal = {Genes},
  year = {2025},
  doi = {10.3390/genes16111281}
}
Kostenlos starten →